Elranatamab binds CD3 on T cell to BCMA on the surface of myeloma cells and induces a potent cytotoxic response against BCMA-expressing myeloma cells by activating T cells (Dhillon 2023b; Rais et al. 2023). Here, TNFRSF17 is linked to plasma cell myeloma.